Quick Answer
Oncotelic Therapeutics, Inc. reported Net Income of -$4.52 million for fiscal year 2024.
Oncotelic Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$4.52M | +42.8% |
| 2023 | -$7.90M | -255.1% |
| 2022 | $5.09M | +154.3% |
| 2021 | -$9.39M | +1.2% |
| 2020 | -$9.50M | -43.2% |
| 2019 | -$6.64M | -831.3% |
| 2018 | -$712.7K | +94.8% |
| 2017 | -$13.81M | -1.2% |
| 2016 | -$13.65M | +0.0% |
| 2015 | -$13.65M | -8.0% |
| 2014 | -$12.65M | -52.8% |
| 2013 | -$8.28M | -2.5% |
| 2012 | -$8.08M | +16.3% |
| 2011 | -$9.65M | +59.4% |
| 2010 | -$23.77M | +3.9% |
| 2009 | -$24.73M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.05M | +68.3% | -476.9% |
| June 30, 2025 | $277.9K | +232.4% | +193.0% |
| March 31, 2025 | -$298.7K | +26.9% | +91.0% |
| September 30, 2024 | -$3.30M | -2965.8% | -1474.8% |
| June 30, 2024 | -$209.8K | +96.9% | +48.7% |
| March 31, 2024 | -$408.7K | +22.2% | -454.4% |
| September 30, 2023 | $115.3K | +114.8% | +101.7% |
| June 30, 2023 | -$6.76M | -142.2% | -1186.0% |
- Oncotelic Therapeutics, Inc. showed an increase of +42.8% in Net Income compared to the prior fiscal year.
- Over the 2009–2024 period, Oncotelic Therapeutics, Inc.’s net income has grown by 81.7% (from -$24.73 million to -$4.52 million).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: